ProQR Therapeutics Revenue and Competitors

Boston, MA USA

Location

$358.4M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • ProQR Therapeutics's estimated annual revenue is currently $37.8M per year.(i)
  • ProQR Therapeutics's estimated revenue per employee is $230,610
  • ProQR Therapeutics's total funding is $358.4M.

Employee Data

  • ProQR Therapeutics has 164 Employees.(i)
  • ProQR Therapeutics grew their employee count by 7% last year.

ProQR Therapeutics's People

NameTitleEmail/Phone
1
Sr. VP InnovationReveal Email/Phone
2
VP Medical AffairsReveal Email/Phone
3
VP - Global Project Leader & Head Project ManagementReveal Email/Phone
4
VP Scientific OperationsReveal Email/Phone
5
VP Head People & OperationsReveal Email/Phone
6
Head Discovery Strategy & New Product PlanningReveal Email/Phone
7
VP Clinical DevelopmentReveal Email/Phone
8
Head IPReveal Email/Phone
9
VP Investor Relations & Corporate CommunicationsReveal Email/Phone
10
SVP InnovationReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is ProQR Therapeutics?

Changing lives is what drives us at ProQR Therapeutics. With a highly energetic team of professionals we strive to make a meaningful impact on the lives of patients and the people around them. By combining innovative technologies and entrepreneurism, ProQR is developing products to potentially transform the lives of patients suffering from severe genetic disorders. If you are up to this challenge and like to be part of our team, check out our website for vacancies: www.proqr.com/careers

keywords:N/A

$358.4M

Total Funding

164

Number of Employees

$37.8M

Revenue (est)

7%

Employee Growth %

N/A

Valuation

N/A

Accelerator

ProQR Therapeutics News

2022-04-17 - Analysts' Recent Ratings Changes for ProQR Therapeutics ...

ProQR Therapeutics (NASDAQ: PRQR) has recently received a number of price target changes and ratings updates: 4/19/2022 – ProQR Therapeutics...

2022-04-17 - ProQR to Present at the Retinal Cell and Gene Therapy ...

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”),...

2022-04-06 - ProQR Therapeutics to Overhaul Development Program, Cut Staff

By Rob Curran. ProQR Therapeutics NV said it would overhaul its drug-development operations, laying off 30% of its employees and a key...

2021-11-04 - ProQR Announces Third Quarter 2021 Operating and Financial Results

Top-line data from pivotal Phase 2/3 Illuminate trial of sepofarsen for CEP290-mediated LCA10 anticipated late Q1/early Q2 2022Five-target collaboration with Lilly highlights significant potential of ProQR’s Axiomer® RNA base-editing platform and strengthens financial position with $50 million i ...

2021-03-24 - ProQR’s RNA therapy on track to pivotal tests in rare, inherited form of vision loss

Netherlands-based ProQR is developing its experimental therapy, QR-421a, as a treatment for Usher syndrome. The rare disorder is caused by mutations to genes that provide the instructions for proteins key to hearing, vision, and balance. The disorder is classified under three types, according to ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$26.3M1656%N/A
#2
$51.8M16535%$39.8M
#3
$29.2M166N/AN/A
#4
$46.1M167-5%N/A
#5
$26.6M167N/AN/A